# 2026-06911: FDA Bids Farewell to Old-School Cancer Drug Tablets

2026-06911, GlaxoSmithKline; Withdrawal of Approval of a New Drug Application for Wellcovorin (Leucovorin Calcium) Tablets, EQ 5 mg Base and EQ 25 mg Base, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-04-10, effective 2026-04-10; PRIA reads it as touching household money (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-06911
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-06911
- Title: GlaxoSmithKline; Withdrawal of Approval of a New Drug Application for Wellcovorin (Leucovorin Calcium) Tablets, EQ 5 mg Base and EQ 25 mg Base
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 18472
- Published: 2026-04-10
- Effective: 2026-04-10
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Bids Farewell to Old-School Cancer Drug Tablets

## Summary

GlaxoSmithKline has stopped selling Wellcovorin tablets and asked the FDA to withdraw its approval for these drugs as of April 10, 2026. This means Wellcovorin tablets (5 mg and 25 mg) can no longer be legally sold or shipped, but pharmacies can use up any leftover stock until it runs out or expires. If needed, GSK can apply again in the future to bring the drug back.

## Abstract

The Food and Drug Administration (FDA or Agency) is withdrawing approval of a new drug application (NDA) for Wellcovorin (leucovorin calcium) tablets, EQ 5 mg base and EQ 25 mg base, held by GlaxoSmithKline, LLC, 2020 Walnut Street, Philadelphia, PA 19104 (GSK). GSK notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

## Effects PRIA read

- Wellcovorin approval withdrawn: cost, medium. The FDA withdrew approval of GlaxoSmithKline's New Drug Application (NDA 018342) for Wellcovorin (leucovorin calcium) tablets, EQ 5 mg and EQ 25 mg, effective April 10, 2026. After that date, introducing or delivering these products into interstate commerce without an approved NDA violates the Fede…
- Existing stock may still be dispensed: benefit, low. Any Wellcovorin (leucovorin calcium) tablets, EQ 5 mg and EQ 25 mg, that were in inventory on April 10, 2026 may continue to be dispensed until inventories are depleted, the products reach their expiration dates, or otherwise become violative—whichever comes first.
- Withdrawal without prejudice to refiling: mixed, low. The FDA's withdrawal of approval is 'without prejudice' to refiling, meaning GlaxoSmithKline may apply in the future to seek approval again for Wellcovorin (NDA 018342).

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-06911 on federalregister.gov](https://www.federalregister.gov/documents/2026/04/10/2026-06911/glaxosmithkline-withdrawal-of-approval-of-a-new-drug-application-for-wellcovorin-leucovorin-calcium)
- [2026-06911 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-04-10/pdf/2026-06911.pdf)

## Related
- [Previous: 2026-06910, Clean Air Act Operating Permit Program; Order on Petition for Objection to Stat…](https://policyrisk.com/federal-register/2026-06910)
- [Next: 2026-06912, Tetrahydrofurfuryl Alcohol From the People's Republic of China: Final Results o…](https://policyrisk.com/federal-register/2026-06912)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-06911 (as of 2026-06-08).
